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Abstract 
Cardiac arrhythmias remain common challenges and are associated with significant 
morbidity and mortality. Effective and safe rhythm control strategies are a primary, yet unmet 
need in everyday clinical practice. Despite significant pharmacological and technological 
advances, including catheter ablation and device-based therapies, the development of more 
effective alternatives is of significant interest to increase quality of life and reduce symptom 
burden, hospitalizations and mortality. The mechanistic understanding of pathophysiological 
pathways underlying cardiac arrhythmias has advanced profoundly, opening up novel 
avenues for mechanism-based therapeutic approaches. Current management of 
arrhythmias, however, is primarily guided by clinical and demographic characteristics of 
patient groups as opposed to individual, patient-specific mechanisms and pheno-
/genotyping. With this State-of-the-Art paper, the Working Group on Cellular 
Electrophysiology of the German Cardiac Society aims to close the gap between advanced 
molecular understanding and clinical decision making in cardiac electrophysiology. The 
significance of cellular electrophysiological findings for clinical arrhythmia management 
constitutes the main focus of this document. Clinically relevant knowledge of 
pathophysiological pathways of arrhythmias and cellular mechanisms of antiarrhythmic 
interventions are summarized. Furthermore, the specific molecular background for the 
initiation and perpetuation of atrial and ventricular arrhythmias and mechanism-based 
strategies for therapeutic interventions are highlighted. Current “hot topics” in atrial fibrillation 
are critically appraised. Finally, the establishment and support of cellular and translational 
electrophysiology programs in clinical rhythmology departments is called for to improve 
basic-science-guided patient management. 
 
Keywords: antiarrhythmic therapy; arrhythmogenesis; cellular electrophysiology; ion 
channels; pathophysiology 
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Introduction 
Cardiac arrhythmias remain a clinical challenge and source of morbidity and mortality in 
developed countries [1]. Research into molecular mechanisms of arrhythmias began more 
than 40 years ago with the discovery of the cellular mechanisms of delayed 
afterdepolarization-induced triggered activity and the mechanisms of reentry [2]. Since then, 
there has been great progress in the understanding of the molecular basis of arrhythmias, 
fueled by technological advances and new experimental methods ranging from cellular 
electrophysiology, genetics and genomics to high resolution microscopy. 
In parallel, there have been amazing developments in treatment options with significant 
pharmacological and technological advances, including catheter ablation and device-based 
therapies [3-8]. However, progress has been largely based on empirical rather than targeted 
mechanism-based approaches. The rapid progress in device and ablation therapies 
compared to the relatively poor outcomes of pharmacological rhythm control treatment may 
have reduced the interaction between clinical electrophysiologists - whose primary interest is 
improving the health and quality of life of patients - and basic electrophysiologists, who are 
driven by novel scientific discoveries, which may take years to reach the clinical setting [2]. 
This state of the art paper summarizes the current knowledge about basic cellular 
electrophysiology and its clinical implications. We will highlight examples where basic cellular 
electrophysiology has contributed to the development of novel translational therapeutic 
strategies. Finally, we will emphasize the importance and advantage of a close interaction 
between clinical and basic electrophysiologists, in order to solve current and future 
challenges in cardiac arrhythmia management [1]. 
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Fundamental mechanisms of cardiac arrhythmias 
Pronounced heterogeneities exist in mechanisms, presentation, treatment and outcome, 
between different cardiac arrhythmias and between patients with the same type of 
arrhythmia. Nonetheless, basic research has identified several important fundamental 
mechanisms of cardiac arrhythmogenesis [9]. In particular, arrhythmias require a vulnerable 
substrate characterized by structural or electrical abnormalities and an acute initiating event. 
Both components can be genetic or, more commonly, acquired due to advancing age or 
concomitant cardiovascular risk factors and can promote abnormal impulse formation 
(ectopic activity) and/or abnormal impulse conduction (resulting in reentrant activity), which 
are considered the major fundamental arrhythmia mechanisms. 
Ectopic activity and reentry 
Ectopic activity is the local generation of action potentials (APs) outside the normal activation 
sequence, which can serve as an initiator of reentry-mediated arrhythmias or maintain the 
fibrillatory process when occurring repetitively at high frequency. Polymorphic ventricular 
tachycardia (VT) or ventricular fibrillation often originate from the Purkinje system, which is 
characterized by distinctive electrophysiological characteristics promoting the generation of 
ectopic excitations and which can be targeted by catheter ablation [10]. In addition, ectopic 
excitations may trigger premature ventricular contractions, which worsen myocardial function 
and contribute to increased mortality in patients with structural heart disease [11]. 
Mechanistically, ectopic activity results from abnormal automaticity or triggered activity 
resulting from early afterdepolarizations (EADs) or delayed afterdepolarizations (DADs) [12]. 
Abnormal automaticity, i.e., spontaneous AP generation from normally quiescent tissue, is 
often mediated by a reduction in ion currents that stabilize the resting membrane potential 
(RMP; e.g., the basal inward-rectifier potassium current, IK1) or an increased activity of 
hyperpolarization-activated pacemaker channels responsible for the funny current, If. On the 
other hand, EADs typically result from excessive AP duration (APD), providing time for 
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reactivation of L-type calcium channels. Finally, DADs result from calcium-handling 
abnormalities, whereby spontaneous calcium-release events from the sarcoplasmic reticulum 
(SR) through so-called ryanodine receptor type-2 (RyR2) channels activate a transient-
inward current, mediated largely by the sodium/calcium-exchanger (NCX), which depolarizes 
RMP and can trigger a new AP. An increased incidence of spontaneous calcium-release 
events can be due to RyR2 dysfunction or due to increased SR calcium load. A classical 
example for the latter are arrhythmias induced by cardiac glycoside intoxication, where 
inhibition of sodium-potassium-ATPase increases the intracellular sodium-concentration. 
This leads to increased cytosolic calcium by reducing the driving force of calcium efflux via 
NCX at resting membrane potential and favoring reverse-mode NCX-mediated calcium-entry 
during the AP. The resulting increased SR calcium load explains the positive inotropic effect 
of cardiac glycosides but also favours spontaneous calcium releases and DADs [13,14]. 
Reentry is considered the primary arrhythmia-maintaining mechanism [15]. Conceptually, 
reentry describes a stable circulating excitation. Reentry can occur around an anatomically 
defined inexcitable core when the product of effective refractory period (ERP) and conduction 
velocity (the so-called wavelength) is sufficiently small, allowing the tissue to become re-
excitable before the reentering impulse arrives. As such, structural remodeling, particularly 
fibrosis, strongly promotes reentry. Reentry may also occur on a purly functional basis. The 
classical “leading-circle” concept, describes reentry around a continuously refractory core 
with a circuit size equal to the wavelength [15]. However, the notion that sodium-channel 
blocking agents are effective in cardioversion of atrial fibrillation (AF) challenged this 
concept, since conduction slowing is supposed to stabilize reentry acording to the “leading-
circle” concept rather than suppressing it. Based on this paradox the “spiral wave” concept 
has been developed, wherein reentry proceeds around an excitable but continuously 
unexcited center and maintenance of reentry depends on the balance between the 
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wavefront’s excitatory currents (the ‘source’) and the properties of the unexcited tissue (the 
‘sink’) [16-18] . 
Spiral wave reentry, often visualized as rotors, represents a major pathophysiological 
concept in AF and rotor ablation has been suggested as potential ablation strategy of 
persistent AF [19,20], which is presently evaluated in various clinical trials (ClinicalTrials.gov 
numbers: NCT02101541, NCT02274857, NCT01924377, NCT02386345, NCT02497248, 
NCT02113761). 
Slow conduction 
Cardiac fibrosis is a hallmark of structural remodeling, promoting slow, heterogeneous 
conduction and spatial dispersion of repolarization by isolating muscle-bundles. Advances in 
clinical imaging methodologies have helped to establish the important role of fibrosis in 
arrhythmogenesis [12]. In parallel, basic science has identified the mechanisms underlying 
the proliferation of fibroblasts and their differentiation into myofibroblasts, which is a central 
response to numerous stress signals activated in many cardiovascular diseases, resulting in 
excessive collagen production and fibrosis [21]. Experimental models have identified the 
major underlying signaling pathways and have indicated that targeting these pathways, either 
using clinically approved drugs (e.g., angiotensin-converting enzyme inhibitors, aldestorone 
antagonists) or through new targets (e.g., microRNAs such as miR-21 or miR-29) may limit 
the development of a proarrhythmic substrate [21]. However, there is increasing awareness 
that such therapy would need to be applied early in the disease process, before extensive 
fibrosis is already present. Other observations suggest that fibrosis and structural alteration 
can be partly reversible, if the underlying condition is effectively treated. 
Reentry-promoting slow conduction is also mediated by gap-junction remodeling, resulting in 
impaired electrical cell-to-cell coupling. Preclinical studies have shown that the expression of 
connexin-43, the predominant constituent of ventricular gap-junction channels, is reduced 
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under pathological conditions (e.g., post-myocardial infarction), contributing to slowed 
conduction, and that gene transfer of connexin-43 reduces the inducibility of ventricular 
tachycardia in pigs, providing an important proof-of-concept for the antiarrhythmic effects of 
targeting the mechanisms underlying slow conduction [22]. 
Alternans 
Cardiac alternans is evident on the surface ECG as beat-to-beat alternations in the ST 
segment or the T-wave. At the cellular level, APD alternans underlies T-wave alternans 
(TWA) in the surface ECG. When APD alternans becomes spatially discordant, a small 
reduction of cycle length may result in unidirectional block followed by reentry and initiation of 
ventricular fibrillation thus providing a mechanistic link between TWA and sudden cardiac 
death (SCD) [23]. Basic science has revealed that cardiac alternans is often caused by 
perturbed cellular calcium signaling [24]. In support of this notion, normalization of SR 
calcium handling in animal models of heart failure (HF) reduced the incidence of cardiac 
alternans and ventricular arrhythmias [25]. Thus, normalization of RyR2 function and SR 
calcium handling may be promising targets to prevent development of alternans and SCD. 
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Inherited channelopathies 
Inherited channelopathies are the prime examples of cardiac diseases in which basic science 
has provided important mechanistic understanding of the pathophysiology. This has led 1) to 
the development of specific diagnostic tests such as ajmaline challenge in Brugada 
syndrome [26], QTc evaluation during stress test in long and short QT syndromes (LQTS, 
SQTS), and importantly 2) to the continued exploration and development of mechanism-
based therapeutic approaches such as late sodium channel block in LQT3 [27] and the use 
of flecainide in catecholaminergic polymorphic ventricular tachycardia (CPVT) [28] that have 
already partially entered the clinical guidelines [29]. 
Long and short QT syndrome 
Both, pathological prolongation (LQTS) and acceleration (SQTS) of cardiac repolarization 
can predispose patients to atrial and ventricular tachycardia (AT/VT) and SCD [29]. Since the 
link of mutations in KCNQ1 and KCNH2/HERG potassium channel and SCN5A sodium 
channel genes to inherited LQTS was established in the 1990s [30,31], mutations in 15 
genes have been linked to LQTS and mutations in 6 genes to SQTS [29]. An increased 
understanding of the biophysical consequences of these mutations (complete loss-of-
function vs. change in voltage-dependence of the respective currents) and the exact location 
of the mutation within the channel (pore-region vs. C- and N-terminus) may have clinical 
relevance for risk prediction [32,33]. 
Characterization of the biophysical properties of the mutated channels and their response to 
sympathetic activity has helped to identify the importance of EADs and sympathetic 
stimulation as proarrhythmic triggers, providing the scientific basis for beta-blocker therapy 
(or left cardiac sympathetic denervation) as mainstay of antiarrhythmic therapy in LQTS [29]. 
The subsequent generation of genetic (knock-out/knock-in) and transgenic (mouse and 
rabbit) models of LQTS has provided important insights into the major role of spatial and 
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temporal APD heterogeneities as arrhythmogenic substrate [34]. Mechanisms underlying 
genotype-specific differences in arrhythmia initiation (sustained sympathetic activity (sports), 
LQT1; sudden sympathetic activation (startle), LQT2) [35] contributing to the clinically 
observed genotype-difference in the efficacy of beta-blocker therapy [36] have been 
identified. The detrimental role of bradycardia and short-long-short sequences as triggers for 
VTs has been observed in patients and confirmed in (animal) models [27,37]. In addition, the 
potential of genotype-specific therapeutic approaches has been explored: In genetic murine 
LQT3 models, with pathologically enhanced late INa, sodium-channel blockers mexiletine, 
flecainide, and the more selective GS967 exert a mechanism-directed, genotype-specific 
antiarrhythmic effect [38-40].Similarly, recent clinical data demonstrate that LQT3 patients 
benefit from QT-shortening and anti-arrhythmic effects of sodium channel blockers 
mexiletine, flecainide, ranolazine, and eleclazine [41-46]. The 2015 ESC guidelines for the 
prevention of SCD thus mention sodium-channel blockers as a potential add-on therapy in 
patients with LQT3 [47]. Moreover, proarrhythmic effects of estradiol due to increased APD 
heterogeneities and EADs has been revealed in transgenic LQT2 rabbit models, contrasting 
with anti-arrhythmic, protective effects of progesterone due to shortening of cardiac 
refractoriness and reduced EAD formation [48]. These data suggest progesterone-based 
therapies might constitute novel antiarrhythmic approaches in female LQTS patients. 
Recent clinical and basic science data suggest subclinical mechanical dysfunction in the 
"electrical" disease LQTS due to close electro-mechanical coupling [49] and a correlation 
between the extent of mechanical dysfunction and arrhythmic risk, strongly suggesting that 
assessment of regional mechanical dysfunction may be helpful to improve future clinical risk 
stratification [50]. 
In SQTS, mechanisms of arrhythmogenesis are less well-understood than in LQTS and 
therefore effective antiarrhythmic treatment options are sparse. The recent development of 
genetic/transgenic animal models of SQTS (zebrafish, rabbit) have the potential to close this 
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gap and help to develop mechanism-based antiarrhythmic therapeutic approaches [Odening 
et al., submitted 2017]. 
Brugada syndrome  
Brugada syndrome (BrS) is characterized by typical precordial ST-segment elevations on the 
surface ECG and an increased risk for SCD caused by ventricular arrhythmia [51]. The 
identification of SCN5A as important disease gene [52] in BrS suggested that the syndrome 
was a monogenetic disorder, similar to LQTS. “Loss-of-function” mutations in other genes, 
implicated in cardiac sodium (GPD1L, SCN1B, SCN3B) or calcium (CACNA1C, CACNB2) 
channel expression were associated with BrS, as well. “Gain-of-function” mutations in 
KCND3, by contrast, demonstrated an involvement of increased transient potassium outward 
current Ito, in the pathogenesis of BrS [53,54]. Interestingly, recent data suggested SCN10A 
and its gene product Nav1.8, primarily expressed in the nervous system and only to a minor 
extent in the heart, as an important disease gene in BrS [55,56], although another study did 
not confirm this view [57]. However, only ~30% of cases may be explained by the 22 
disease–associated genes known so far, pointing to a multifactorial origin of the disorder. 
This view was fueled by recent findings that hearts of BrS patients often show subtle 
structural changes, in particular in the right ventricular outflow tract (RVOT), suggesting a 
distinct cardiomyopathy [58]. This is pathophysiologically important as such regions - either 
caused by channelopathy or even more complex mechanisms - may give rise to areas of low 
voltage and electrical zig-zag conduction that constitute a substrate for microreentry as 
arrhythmogenic basis of the syndrome. Observations in BrS patients undergoing 
electrophysiological study and reports of successful radiofrequency ablation of critical areas 
in the RVOT [59], further substantiated this pathomechanistic idea, building the backbone of 
the depolarization hypothesis. Accordingly, localized slow conduction in the RVOT 
constitutes the origin of typical ECG changes in right precordial leads. 
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The repolarization hypothesis, by contrast, postulates an imbalance of ion currents during 
phase 1 of the right ventricular epicardial AP, mediated by transmural differences in the 
outward potassium current Ito and genetic or drug-induced reduction of INa, underlying the 
ECG pattern and the induction of arrhythmias in BrS [60]. 
Regardless which of the two hypotheses more precisely reflects the underlying mechanisms, 
it is an important achievement of basic electrophysiological research that a mismatch of 
depolarizing current (in particular INa) and Ito as well as distinct phases of bradycardia, are 
major drivers of arrhythmogenicity in BrS. Therefore, modulation of the INa/Ito relation has an 
important role in current clinical diagnostic, risk stratification and therapeutic approaches in 
BrS, including (1) the application of sodium current blockers as diagnostic test for inducibility 
of Brugada ECG (ajmaline or flecainide challenge) [26], (2) the use of quinidine to decrease 
arrhythmic burden in BrS patients by inhibiting Ito [61], (3) the use of isoproterenol or other β-
adrenergic stimuli in arrhythmogenic storm to increase depolarizing current (in particular L-
type calcium current; ICa,L) and avoid bradycardia [61], (4) avoidance of drugs that decrease 
INa or increase Ito (see www.brugadadrugs.org) and (5) avoidance of fever to prevent 
temperature-induced INa/Ito mismatch [62]. However, currently, the only way to safely prevent 
SCD is the implantation of an implantable cardioverter defibrillator (ICD), indicating an urgent 
need for basic and translational research to provide better mechanism-based diagnostic and 
therapeutic strategies. 
Catecholaminergic polymorphic ventricular tachycardia 
CPVT is a highly lethal inherited arrhythmogenic disorder characterized by episodes of 
polymorphic VT and SCD in the setting of exercise or emotional stress. In recent years 
significant progress has been made to understand the underlying mechanisms, which has 
positively impacted the therapy of CPVT patients [63]. The molecular basis of CPVT has 
mostly been attributed to dysfunction of the RyR2 channel, promoting calcium-handling 
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abnormalities, DADs and triggered activity, particularly during increased sympathetic tone 
when SR calcium load increases and RyR2 channels become hyperphosphorylated, further 
promoting their dysfunction [64]. In  65% of CPVT patients, this RyR2 dysfunction is due to 
mutations in the RYR2 gene itself (CPVT1), but mutations in proteins regulating RyR2 
function as part of the macromolecular complex that controls SR calcium release (e.g., 
calsequestrin-2 or calmodulin), which can indirectly promote RyR2 dysfunction, have also 
been described [64,63].  
Recent data from animal models of CPVT suggest that the primary defects in calcium 
handling may also cause sinoatrial node (SAN) dysfunction, fibrosis, atrial arrhythmias, 
exaggerated left ventricular (LV) hypertrophy and HF [65]. These findings may explain why 
some affected patients exhibit bradycardia and atrial arrhythmias, in addition to CPVT. 
Moreover, they provide a direct mechanistic link between a primary calcium handling disease 
and structural remodeling in the heart. This might have more widespread implications for 
other diseases. 
The identification of the underlying arrhythmogenic mechanisms has played an important role 
in the treatment of CPVT patients, which involve inhibition of sympathetic activity (beta-
blockers or left cardiac sympathetic denervation) and the use of flecainide. The role of 
flecainide in CPVT represents a prime example of the interaction between basic scientists 
and clinicians. It was initially established in mice and applied as a proof of concept in two 
CPVT patients [28], but has since then become a class IIa guideline recommendation [29]. 
However, the exact antiarrhythmic mechanism of flecainide remains a topic of debate and 
may involve a combination of sodium channel block (preventing triggered activity), inhibition 
of RyR2 (reducing the likelihood of spontaneous SR calcium-release events), or indirect 
effects on intracellular calcium handling due to changes in intracellular sodium [66,67]. 
Based on the underlying mechanisms of CPVT, RyR2 dysfunction is considered a promising 
therapeutic target. Several RyR2-stabilizing compounds, including K201/JTV-519, S107 and 
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carvedilol-analogues, have indeed shown promise in preclinical studies [68]. Of particular 
clinical interest are the effects of dantrolene, an RyR-stabilizing drug approved for the 
treatment of malignant hyperthermia, which also has antiarrhythmic effects in CPVT patients 
[69,70]. 
Electrical conduction defects 
Cardiac conduction defect (CCD) also comprises primary genetic forms, although most 
cases arise from age-related fibrotic degeneration of the conduction system. The yield of 
genetic testing in CCD is ~30 % [71]. Isolated CCD can be caused by mutations in SCN5A 
(progressive familial heart block 1a) [72] or TRPM4 (progressive familial heart block 1b) [73]. 
In association with cardiomyopathy, CCD was linked to LMNA [74] and PRKAG2 mutations 
[75]. Patients with such mutations are also at risk of ventricular arrhythmias rendering further 
decision making regarding ICD implementation important. Furthermore, mutations in NKX2-5 
[76] and TBX5 [77] cause CCD in association with congenital heart disease. Thus, evidence 
for genetic forms of CCD can significantly improve stratification of patients, as it constitutes a 
prognostic indicator for the course of disease with or without a syndromic co-morbidity. 
Hereditary sinus node disease 
Loss or dysfunction of SAN cells results in sinus node disease (SND), comprising sinus 
bradycardia, SAN block or arrest and bradycardia-tachycardia syndrome (BTS) [78]. In the 
majority of cases SND is “idiopathic” and occurs age-dependently either by cellular 
dysfunction of SAN cells or degeneration of the formerly intact SAN.  
Loss-of-function mutations in SCN5A are an established pathomechanism (sick sinus 
syndrome 1). Electrophysiological studies and computational modeling established that 
mutated channels cause either abnormally slow pacemaking or produce SAN exit block [78]. 
Furthermore, mutations in HCN4 underlying a significant proportion of the pacemaker current 
If in the SAN, cause hereditary SND (sick sinus syndrome 2) and BTS, respectively [79-81]. 
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HCN4 gain-of-function mutations are associated with inappropriate sinus tachycardia. 
Functional investigations showed that HCN4-R524Q mutant channels, heterozygously 
carried by affected family members, have an increased cAMP sensitivity resulting in an 
augmented funny-current at baseline leading to a faster resting heart rate [82]. Thus, 
inappropriate sinus tachycardia in part has a genetic basis, which raises the possibility of 
inheritable traits. 
Importantly, investigation of If and its underlying ion channels, built the groundwork for 
ivabradine, the first clinically available If blocker targeting impulse formation in the SAN. This 
pharmacological mechanism is successfully used to treat patients with chronic stable angina 
and HF [83]. 
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Drug-induced, reversible “channelopathies” 
Various drugs can phenocopy ECG features and arrhythmias of genetic channelopathies by 
interacting with different cardiac ion channels, causing for example acquired LQTS and BrS - 
particularly in patients harboring single-nucleotide polymorphism variants or even silent 
disease-causing mutations [84]. Most drugs causing acquired LQTS block HERG-encoded IKr 
[85]. However, drugs may also cause acquired LQTS by blocking other currents such as IKs 
(e.g., isoflurane) or IK1 (e.g., midazolam) [86]. Drug-induced BrS is often caused by sodium-
channel-blocking class 1 drugs [84]. Overall, acquired drug-induced “channelopathies” and 
arrhythmias are much more prevalent than rare genetic forms and exploring their 
mechanisms has important pre-clinical and clinical implications to prevent adverse drug 
effects. 
Safety pharmacology 
Every new pharmacological agent under development undergoes extensive cardiac safety 
testing to exclude any proarrhythmic liability [85]. Until recently, cardiac safety assays 
predominantly involved high-throughput screening of HERG blockade early on and a so-
called ‘thorough QT study’ assessing repolarization prolongation in humans later on in drug 
development. However, extensive basic science studies have established that HERG 
screening alone has limited sensitivity and specificity to identify proarrhythmic compounds, 
which has prompted a more integrative approach to assess the cardiac safety of new 
compounds. The Comprehensive In vitro Proarrhythmia Assay (CIPA) initiative [87] 
advocates the use of 1) screening of ion-channel-blocking effects beyond HERG alone, 2) in 
silico integration of these findings to assess overall effects on ventricular repolarization and 
3) use of integrated biological systems such as induced pluripotent stem cell-derived 
cardiomyocytes (IPSC-CM). 
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Ventricular arrhythmia in subjects with structural heart disease 
Ventricular arrhythmias remain a major contributor to increased mortality in patients with 
ischemic or nonischemic cardiomyopathy [47]. Underlying pathophysiology, risk markers and 
current treatment options are outlined below. Outflow tract tachycardia and idiopathic LV 
tachycardia are not discussed due to lack of significant basic science data. 
Ischemic cardiomyopathy (ICM) 
Ischemia results in release of reactive oxygen species, increase in intracellular sodium due to 
sodium/hydrogen exchange and inhibition of the sodium/potassium-ATPase triggered directly 
by hypoxia or secondary to ATP depletion. Within hours after ischemia onset, associated 
cytokine- and chemoattractant-mediated endothelial dysfunction, apoptosis, autophagy, 
platelet aggregation and micromebolization, and neutrophil accumulation as well as 
macrophage and T-cell-mediated cell-damage occur [88,89].  
While acute ischemia/reperfusion injury primarily leads to ventricular fibrillation, myocardial 
infarction related regional scars and especially the border zone between infarcted and vital 
myocardium are an important substrate for VT occurrence in ICM: Infarct related changes in 
excitability and conduction velocity as arrhythmogenic substrate lead to perpetual reentrant 
VT (see also Figure 2). 
Pharmacological treatment of ventricular fibrillation is currently limited [47]. Class I 
antiarrhythmic drugs are contraindicated due to increased risk for arrhythmia associated 
sudden cardiac death as shown in the “Cardiac Arrhythmia Suppression Trial” (CAST) [90]. 
After the CAST study had abolished the use of Class I antiarrhythmic drugs in ICM, several 
antiarrhythmic compounds underwent evaluation, as the alternative compound amiodarone 
besides its antiarrhythmic potential had shown to have cumulative toxicity in many body 
organs. 
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Class III antiarrhythmic compound, MS551 (nifekalant), was described to have antiarrhythmic 
properties shortly after the CAST results had been published [91]. The pyrimidine derivative 
leads to frequency dependent AP-prolongation. It has voltage- and frequency dependent 
inhibitory properties on HERG encoded IKr with high affinity for “open state” of IKr. As 
described above, this is known to possibly induce an aquired form of QT-interval 
prolongation with the risk for fatal polymorphic tachycardias including torsades de pointes. 
However, different from other class III agents, it also has agonistic/facilitating effects on 
HERG current [92]. Nifekalant has a high potency for destabilization and early termination of 
spiral wave reentry and to prevent VT/ventricular fibrillation after acute myocardial infarction. 
It also improves electrical defibrillation efficacy in this setting [93]. However nifekalant is only 
approved in Japan for the treatment of life threatening ventricular tachyarrhythmias. 
Another class III antiarrhythmic compound, SSR149744C (celivarone), is like amiodarone a 
benzofuran derivative, however, different from amiodarone it is not iodinated, thus has less 
organ toxicity [94]. Celivarone has antiadrenergic and angiotensin II antagonistic effects and 
is a multi ion-channel blocker. Similar to amiodarone it is a weak sodium channel blocker 
with additional IKr, IKs, and IK1 blocking properties, but less effective in IK,ACh-, IKv1.5-, or ICa,L- 
blockade [94]. In the ICARIOS-trial, celivarone showed a 46% (non-statistically significant) 
reduction in VT/-ventricular fibrillation triggered ICD shock therapies, however in the 
ALPHEE Study, celivarone was not effective for the prevention of ICD interventions or death 
[95]. 
To date, according to the European Society of Cardiology (ESC) guidelines, only 
betablockers (in the non-acute phase of MI) and amiodarone are recommended in ischemia 
related ventricular fibrillation or VT associated with heart failure [47]. Therefore it seems 
urgently necessary to search for other treatment options of ischemic cardiomyopathy 
associated arrhythmias.  
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A very recent and interesting approach comes from experimental data from a pig animal 
model that evaluated cardiac remodeling in an ischemia/reperfusion setting with or without 
administration of class III antiarrhythmic compound dronedarone [96]. In a meticulous 
transcriptome profiling and combined proteome analysis of post-infarction remodeling the 
authors found the levels of 879 transcripts in the infarction border zone, 7 transcripts in the 
myocardial infarction area, as well as 51 proteins in the unaffected left ventricle and 15 
proteins in the border zone affected by dronedarone treatment. All findings were supported 
by disease/function charts and an integrated network established by combined “omics”. 
Table 1 shows transcriptomics with most predominant changes in gene expression. Besides 
the fact that dronedarone is not approved for ventricular arrhythmias, this genuine approach 
highlights the importance of myocardial infarction border zone in ICM. Secondly, it may lead 
to similar evaluation approaches for future antiarrhythmic compounds that can improve our 
understanding of arrhythmogenesis on a subcellular transcriptome and proteome level. 
Autonomic nervous system 
Autonomic imbalance characterized by increased sympathetic activation and 
parasympathetic withdrawal along with changes in density and spatial distribution of the 
intrinsic efferent innervation of the ventricles may account for the timing of clinical 
presentation of arrhythmias after ventricular injury [97]. Sympathetic hyperinnervation in the 
ventricle occurs post-MI and has been linked to ventricular arrhythmias. Whereas nerve 
growth factor (NGF) stimulates axon growth, its precursor, proNGF, triggers axon 
degeneration and may be involved in regional denervation after myocardial injury. 
Additionally, denervated reperfused infarcts display -adrenoreceptor supersensitivity [98]. 
Both sympathetic hyperinnervation and denervation of the ventricles can lead to 
heterogeneous -adrenoreceptor activation, either through localized catecholamine release 
or localized -adrenoreceptor supersensitivity. This non-uniform sympathetic activation 
increases the risk of focal triggers and creates gradients of repolarization, increasing the 
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susceptibility to reentry. Attempts to therapeutically reduce sympathetic activation or 
sympathetic nerve sprouting (e.g. by cardiac sympathetic denervation or renal denervation) 
[99-101] or to increase cardiac parasympathetic tone (e.g., by baroreceptor stimulation) [102] 
reduce arrhythmias in animal models and selected cohorts of patients. 
Non-ischemic cardiomyopathy 
Non-ischemic cardiomyopathies include genuine dilated or congestive cardiomyopathy 
(DCM) and special cases such as arrhythmogenic right ventricular cardiomyopathy/dysplasia 
(ARVC/D).  
While in ICM usually focal areas with post ischemic/MI fibrosis and scarring can be found 
that lead to reduced myocardial contractility, in DCM the impaired myocardial contractility is 
generally dispersed. 
Pathophysiology of VT generation in DCM is as complex as its variety of genetic causes. 
Nowadays, an abundance of genes and alleles that contribute to phenotypic DCM are 
identified [103]. Gene alterations of TTN (coding for Titin, 12-25% of DCM), LMNA (coding 
for Lamina/C, 4-8% of DCM), DES, VLC and FLNC (coding for cytoskeletal proteins, each 
around 1% of DCM) significantly contribute to the DCM phenotype [103]. While DSP, coding 
for desmoplakin, also contributes to DCM, other desmosome changes instead result in 
ARVC/M. Loss of RNA-binding protein 20 (RMB20), which is a RNA-binding protein of 
spliceosome of TTN and calcium/calmodulin-dependent protein kinase II (CaMKII) delta, 
leads to a clinically aggressive form of DCM [104]. Despite similar left ventricular function, 
altered calcium handling increased arrhythmic burden (44% vs. 5%) when RBM20 mutation 
carriers were compared to TTN mutation carriers [104]. Therefore, ICa,L-blockers may 
possibly reduce arrhythmia burden in this disease entity. Besides playing a role in LQTS3 
and BrS, SCN5A mutations also can lead to DCM or ARVC/D [105]. In some cases with a 
gain-of-function mutation in the sodium channel (i.e. in p.R222Q mutation carriers) Class I 
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antiarrhythmic agents have been reported to decrease arrhythmogenic burden and improve 
left ventricular function [105]. 
In ARVC/D, several desmosomal and non-desmosomal gene mutations have been identified 
to induce phenotypic disease. Desmosomal genes include plakophilin 2, desmoglein 2, and 
desmoplakin gene mutations contributing to half of all cases [106]. Non-desmosomal 
changes include amongst others gene mutations in the RyR2, phospholamban, Lamin A/C, 
Desmin, Titin and transforming growth factor 2 [106]. Pharmacological treatment options 
include betablockers in all ARVC/D phenotype patients, as well as sotalol, amiodarone, and 
mexiletine. In selected patients epicardial ablation may be considered. 
Besides antiarrhythmic drugs, experimental data of mouse models have shown reduced 
structural and electrical remodeling leading to arrhythmia reduction by blockade of the renin-
angiotensin-system. The direct renin inhibitor aliskiren was shown to have antiarrhythmic 
potential by reestablishing normal ventricular conduction velocities due to restoration of 
connexin 43 expression in a DCM mouse model [107]. Also, the angiotensin II receptor 
antagonist candesartan was able to partially reverse pro-arrhythmic down-regulation of Kv4.2 
(Ito channel protein), KChIP2 (auxiliary subunit of Kv4.2), and Kv1.5 (IKur channel protein) in 
another DCM mouse model [108]. 
To date, however, most treatment approaches in DCM are symptomatic or prophylactic and 
not driven by pathophysiologic understanding of the disease or underlying genetic pathology. 
Therefore, the main goal for the future is to gain further knowledge about underlying disease 
pathology on the organ, cellular, and subcellular levels in order to translate this knowledge 
into mechanism-based therapeutic approaches. 
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Atrial arrhythmias 
Atrial arrhythmias, particularly AF, are the most common cardiac rhythm disorders and are 
associated with increased rate of stroke, HF and death. Great efforts have been undertaken 
to understand the underlying arrhythmic mechanisms and improve treatment options. 
Although there are now many sophisticated therapeutic options available, antiarrhythmic 
therapy remains unsatisfactory [109]. In contrast, pacemakers are accepted standard therapy 
for patients with bradycardia. Similarly, patients with accessory-pathway or AV-nodal reentry 
syndromes, such as Wolff-Parkinson-White syndrome, are usually successfully treated with 
ablation therapy [110]. A thorough understanding of the molecular mechanisms underlying 
the latter has had little impact on therapeutic options and these arrhythmias will therefore not 
be discussed in further detail. 
Atrial tachycardia (AT) 
ATs are subdivided based on underlying mechanisms into focal tachycardias and 
macroreentrant tachycardias, also designated as atrial flutter [111]. Focal ATs commonly 
arise in the absence of preexisting structural heart disease and can occur at any age with no 
gender preference [112]. The autonomous nervous system likely contributes to the initiation 
of focal AT, which can be triggered by changes in posture, belching and swallowing. 
Pathomechanism of focal AT include abnormal automaticity (19 %), triggered activity (25 %) 
or microreentry (56 %) [113]. 
Focal AT due to triggered activity are likely mediated by DADs. Focal AT may also be caused 
by microreentry, which refers to a small reentrant loop which is below the resolution of 
current mapping systems [111]. Adenosine can be used to distinguish reentry from other 
mechanisms underlying AT. Adenosine binding to A1-receptors leads to dissociation of Gi-
proteins and to activation of a repolarizing potassium current (IK,ACh), due to direct interaction 
with the Gi-protein -subunit ). The resulting stabilization of the RMP terminates focal AT 
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caused by afterdepolarizations, transiently suppresses AT due to abnormal automaticity, but 
does not affect AT based on reentry mechanisms [114]. 
The current knowledge surrounding underlying AT mechanisms is not yet sufficient to guide 
antiarrhythmic drug choice, but may help to understand why certain treatment options may 
be effective in some patients while ineffective in others. There is hope that the future 
development of selective drugs may provide new therapeutic options for mechanism-based 
therapy of AT [115]. 
Atrial fibrillation 
a. Remodeling; progression of AF 
The "atrial fibrillation begets atrial fibrillation" paradigm [116] states that the longer AF 
persists, the higher the inducibility and stability of AF, i.e. the higher the likelihood that AF will 
perpetuate. These basic research findings recapitulate the clinical observation that AF is a 
highly progressive disease [109,117]. The progressive nature of AF is caused by atrial 
remodeling processes on the cellular and tissue level, and basic research has been 
instrumental in unravelling these processes [9]. Atrial remodeling comprises electrical, 
contractile, structural and calcium handling remodeling. Electrical remodeling is 
characterized by a dramatic reduction in atrial ERP caused by shortening of atrial myocyte 
APD. The latter is due to altered regulation and expression of ion channels, e.g. reduced ICa,L 
and transient outward potassium (Ito) current and increased inward rectifier potassium 
currents and TASK-1 (K2P 3.1) current [118,117,119,120]. Contractile remodeling is caused 
by multiple mechanisms including impaired calcium handling and dysregulation of the 
sarcomeres and myofilaments [117]. Prominent features of structural remodeling are atrial 
dilatation, atrial myocyte hypertrophy and fibrosis, which creates a substrate for AF [117]. 
Calcium-handling remodeling includes altered expression and/or regulation (e.g. 
phosphorylation) of L-type calcium channels, NCX, RyR2, SERCA2a or CaMKII [121-123]. 
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Calcium-handling abnormalities 1) contribute to electrical, contractile, structural and 
intracellular signalling remodeling; 2) may provide both a trigger (e.g. by spontaneous SR 
calcium release triggering DADs) and a substrate for AF (by contributing to electrical and 
structural remodeling); and 3) may be both a cause and consequence of AF [123]. 
There are notable differences in the time course and reversibility of electrical and structural 
remodeling with important clinical ramifications. Electrical remodeling is an early event 
starting within hours or days after initiation of AF and is reversible upon restoration of sinus 
rhythm [116]. Fibrosis (structural remodeling), on the other hand, is a late event [12] and is 
considered poorly reversible. In patients, the degree of atrial fibrosis correlates with the 
occurrence of postoperative AF as well as with the persistence and recurrence of AF 
[124,125]. Thus, a high degree of atrial fibrosis may be regarded a marker of terminally-
remodelled atria highly susceptible to AF. These findings on the time course and progression 
of atrial remodeling may explain the clinical observation that cardioversion and catheter 
ablation for rhythm control are more successful in younger patients with shorter history of AF 
and less atrial structural remodeling [109]. They stress the clinical paradigm that, in order to 
be treated successfully, AF has to be diagnosed early, i.e. before the development of 
excessive structural remodeling, which may represent a "point of no return" toward sinus 
rhythm. 
Recent evidence from cellular electrophysiology indicates that calcium-handling remodeling 
exhibits important differences between paroxysmal and chronic AF [122,121]. These findings 
have important clinical implications: Firstly, they indicate that paroxysmal and chronic AF 
may be different entities and that (calcium handling) remodeling does not necessarily 
represent a continuum from paroxysmal to chronic AF, where a certain alteration simply 
progresses and aggravates over time. Secondly, they suggest that optimal treatment for 
paroxysmal and chronic AF could differ and, ideally, should be tailored to the individual 
remodeling processes in a given patient. 
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The “complex of structural, architectural, contractile or electrophysiological changes affecting 
the atria with the potential to produce clinically-relevant manifestations” has been 
summarized as “atrial cardiomyopathy” [126]. 
 
b. Mechanism-based stratification of AF subtypes: impact of comorbidities 
Patient stratification and antiarrhythmic therapy planning relies primarily on symptoms and 
the duration of AF (i.e., paroxysmal, persistent, long-standing persistent, or permanent) 
[109]. This classification is limited by a lack of regard for arrhythmia burden, the predominant 
underlying mechanism of the arrhythmia, or the severity of the atrial substrate. Specifically, 
the impact of basic scientific findings on AF categorization and therapeutic decision making 
has been low in the past, despite significant advances in the field [127]. From a cellular 
electrophysiologist’s perspective, among the most striking differences between AF patients 
are changes in APD of atrial myocytes. In patients with persistent or permanent AF but 
without pronounced LV dysfunction, the “classical” mechanism of atrial arrhythmogenesis is 
observed, characterized by reentry-promoting shortening of atrial APD [118,117,121]. In 
these patients, inhibition of repolarizing K+ channels that are expressed in human atrium by 
class III antiarrhythmic drugs is expected to be particularly effective in suppressing AF. The 
coexistence of HF with severe LV dysfunction poses a clinically significant therapeutic 
challenge attributed to a distinct atrial substrate that was recently studied in detail. In affected 
patients with paroxysmal AF, atrial APs are prolonged [128]. The hypothesis that 
manipulations to activate potassium currents could exert antiarrhythmic effects in these 
cases remains to be tested in translational approaches. Of note, HF-associated APD 
prolongation and APD shortening in chronic forms of AF offset each other, resulting in 
apparently normal APD in patients with long-standing persistent AF and severe LV 
dysfunction. 
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The development and application of methodologies evaluating the extent of atrial remodeling 
in patients such as electro-anatomic mapping or late gadolinium enhancement magnetic 
resonance imaging (LGE-MRI), as well as mapping techniques applied during ongoing 
arrhythmias (e.g., mapping of focal or re-entrant activity) may help to improve arrhythmia 
characterization and the initiation of individualized treatment of AF patients. In translational 
research strategies evaluating antiarrhythmic concepts to be applied in patients with 
paroxysmal AF or following rhythm control by ablation or cardioversion, the use of cells 
obtained from subjects with persistent or even permanent AF exhibiting different cellular 
electrophysiological mechanisms constitutes a limitation that requires careful consideration. 
Cells obtained from specific patient populations targeted by antiarrhythmic interventions 
(e.g., paroxysmal AF) should be preferred when studying antiarrhythmic concepts. 
c. Vagal AF 
AF patients with structurally normal hearts tend to show a vagal pattern of AF onset 
(nocturnal AF, AF during rest or after exercise), while patients with structural heart disease 
tend to show a sympathetic pattern (AF during daytime or during exercise) [129]. Other 
studies in “lone” AF patients suggest that AF onset might be associated with a combined 
symatho-vagal activation rather than with an increase in vagal or sympathetic drive alone 
[117]. Nocturnal arrhythmias might be triggered by autonomic activation due to sleep 
disordered breathing like obstructive sleep apnea. During obstructive respiratory events a 
profound peri-apneic vagal activation [130] followed by combined sympathetic activation at 
the end of the apnea during the arousal reaction may trigger AF [131]. Additionally, 
endurance athletes are more likely to develop AF than non-athletes. The type, intensity and 
amount of sport appears to influence the risk of developing AF and different mechanisms 
involving increased vagal tone at rest, increased cardiomyocyte-sensitivity to cholinergic 
stimulation [132], structural atrial remodeling, sinus bradycardia and genetic predisposition 
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may contribute to AF in athletes [133]. Treatment of sleep apnea or detraining in athletes 
may reduce AF burden in these patients. 
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Classical and novel antiarrhythmic drug paradigms 
In contrast to the inherited channelopathies, where insights into arrhythmia mechanisms 
have greatly advanced antiarrhythmic drug therapy, the ICD remains the cornerstone of 
antiarrhythmic therapy in patients at high risk for ventricular arrhythmias due to acquired 
conditions [47]. Indeed, with the exception of beta-blockers, antiarrhythmic drugs have not 
shown a consistent efficacy in the primary management of arrhythmias in this setting, 
perhaps because currently available antiarrhythmic drugs were mainly identified based on 
chance observations during clinical studies, without a precise understanding of the molecular 
mechanisms underlying initiation and maintenance of arrhythmias [115]. 
The discovery of sodium-channel block as the major mechanism underlying antiarrhythmic 
effects of quinidine led to the development of class I antiarrhythmic agents such as flecainide 
and propafenone. Improved understanding of the fundamental biophysical determinants of 
state-dependent block of sodium channels subsequently led to the subdivision of agents into 
classes IA, IB and IC by Vaughan Williams [134]. Ranolazine is a multi-channel blocker, 
primarily inhibiting IKr and the late component of the cardiac sodium current, which was 
originally developed as an antianginal drug. Several studies have supported the therapeutic 
potential of ranolazine for ventricular arrhythmias. However, the large, randomized, double-
blind, placebo-controlled Ranolazine Implantable Cardioverter-Defibrillator (RAID) trial in 
which high-risk ICD patients with ischemic or nonischemic cardiomyopathy were randomly 
assigned to ranolazine or placebo only found a non-significant 16% reduction in the primary 
composite outcome of VT/ventricular fibrillation or death. Furthermore, although more 
selective blockers of the late sodium current, such as eleclazine, showed strong 
antiarrhythmic effects in animal studies, all subsequent clinical trials (ClinicalTrials.gov 
numbers: NCT02104583, NCT02291237, NCT02300558) have recently been discontinued . 
Besides beta-blockers, amiodarone is most often used due to contraindications for other 
antiarrhythmic drugs in the presence of advanced structural heart disease, which is common 
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in this population. The antiarrhythmic effects of amiodarone were also a coincidental 
discovery during amiodarone use in the therapy of angina. Further investigations revealed 
that potassium-channel inhibition by amiodarone reduces the likelihood of reentry by 
prolonging APD and ERP. In addition, amiodarone blocks sodium and calcium channels and 
inhibits the effects of alpha- and betaadrenoceptors, thereby possessing properties of all four 
Vaughan Williams classes of antiarrhythmic agents. Therefore combined blockade of multiple 
ion channels has recently been suggested to underlie the relatively high anti-AF efficacy of 
amiodarone [135]. However, amiodarone’s extracardiac toxicity has motivated the search for 
alternatives [136]. Dronedarone is the first amiodarone-analog and exhibits reduced toxicity 
and lipophilicity. Initial clinical studies with dronedarone did not show significant 
extracardiovascular toxicity and the ATHENA trial demonstrated a reduction in stroke 
associated with dronedarone use in AF patients [137]. However, dronedarone is less 
effective in maintaining sinus rhythm than amiodarone and it is contraindicated in patients 
with HF [109]. 
A number of alternative antiarrhythmic strategies for patients with ventricular arrhythmias 
have been proposed based on preclinical studies. Among these, inhibition of CaMKII, which 
appears to play a nodal role in both atrial and ventricular arrhythmias, has received 
significant interest. CaMKII activity is increased in multiple cardiovascular diseases including 
AF and HF [121], and targets a large number of ion channels and calcium-handling proteins, 
including L-type calcium channels, RyR2 and phospholamban. Recent studies have 
highlighted the antiarrhythmic potential of several new CaMKII inhibitors, particularly for 
conditions in which CaMKII activity is increased. Some of these compounds are currently 
undergoing clinical testing for rheumatoid arthritis [138], but their antiarrhythmic potential has 
not yet been evaluated in clinical studies. Alternatively, since RyR2 dysfunction plays a major 
role in maladaptive cardiac remodeling, e.g., in the setting of HF [139], RyR2 stabilizing 
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drugs (e.g., K201/JTV-519, S107, carvedilol-analogues), may have a more general 
therapeutic use, beyond their role in RyR2-associated channelopathies like CPVT.  
Atrial specific antiarrhythmic drugs 
Despite the rapid development of radiofrequency ablation strategies for the treatment of AF, 
their effectiveness and safety remain inadequate. Furthermore, these methods can only be 
applied in a restricted number of patients and therefore pharmacological approaches remain 
clinically relevant, especially due to the large and growing size of the AF population [109]. 
The ongoing search for new agents against AF has led to the development of atrial-selective 
antiarrhythmic approaches [140]. 
Vernakalant and ranolazine, for example, are the first approaches to selectively target atrial 
sodium-channels by taking advantage of the biophysical differences between atrial and 
ventricular channels [141]. In atrial tissue, a higher fraction of sodium channels is in the 
inactivated state because of the more depolarized resting membrane potential. Since 
vernakalant and ranolazine bind with higher affinity to activated/inactivated sodium channels 
than to channels in the closed state, this may contribute to an atrial specific effect on peak 
sodium current of these drugs [141,142]. In addition, ranolazine predominantly inhibits late 
sodium current, which is increased in patients with AF and has been suggested to contribute 
to AF pathophysiology [143,144]. 
Another approach to developing atrial specific compounds aims to target potassium-channels 
which are predominantly expressed in the atrium, such as IKur, IK,ACh., two-pore K+-channels 
or Ca2+-dependent K+-channels [145]. Interestingly, some of the already available 
antiarrhythmic agents, such as flecainide, amiodarone, quinidine, chloroquine or verapamil, 
inhibit some of these atrial-selective K+-channels, which may contribute to their 
antiarrhythmic effect in AF [145]. 
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The unique effectiveness and low arrhythmogenic potential of amiodarone has been 
attributed, amongst other factors, to its broad spectrum of ion-channel blocking effects 
[115,145]. Therefore, identification of specific combinations of ion-channel modulating 
activities could optimize antiarrhythmic efficacy and atrial selectivity. Accordingly, the 
combination of ranolazine and amiodarone, dronedarone or dofetilide has higher 
antiarrhythmic efficacy, compared with either drug alone [146,147] and AF-selectivity of 
sodium channel blockers can be improved by adding potassium channel blockade [148]. In 
the HARMONY trial the combination of ranolazine and dronedarone showed synergistic 
effects in reducing AF burden in paroxysmal AF patients [149]. However, at present, 
currently available evidence is insufficient to recommend antiarrhythmic drug combinations 
and further research is necessary to define the required channel blocking profile and to 
validate these approaches in clinical studies. 
Basic research during recent years on the mechanisms underlying AF pathology also led to 
the identification of new potential antiarrhythmic approaches, including the normalization of 
atrial calcium-handling abnormalities, atrial metabolism or autonomic-tone manipulation. 
These are currently not implemented in therapeutic strategies and we refer the interested 
reader to recent reviews [12,115]. 
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Opportunities, challenges and future perspectives 
Personalized diagnostic and therapeutic approaches 
An increased understanding of patho-mechanisms underlying specific disease subtypes may 
open the avenue for more specific, personalized therapies. In monogenic channelopathies 
such as LQTS, for example, this has already led to genotype-specific approaches, e.g. late 
sodium channel blocker therapy in LQT-3 [27]. However, even mutation-specific, 
personalized therapies may develop as a) different mutations may convey pronounced 
differences in arrhythmic risk [32] and b) pronounced mutation-specific differences are 
observed in response to a given antiarrhythmic drug. The SQTS gain-of-function mutations 
HERG-N588K and KCNQ1-V307L, for example, alter the extent of IKr/IKs-blocking effects of 
various beta-blocking agents [41] and HERG-N588K may similarly diminish IKr-blocking (and 
hence therapeutic) effects of a variety of class I and III agents such as sotalol, quinidine, and 
amiodarone [150]. Here, the development of patient-specific hiPSC-CM may help to test 
personalized anti-arrhythmic approaches [151]. 
Not only in monogenic arrhythmia disorders but also in more common arrhythmias such as 
AF, a more detailed classification of the disease into "mechanistic" subtypes (see chapter 
Mechanism-based stratification of AF subtypes) may promote patient-oriented rather than 
generalized therapeutic strategies. miRNAs may help to characterize the substrate or the 
electrical phenotype in individual AF patients and predict the outcome of interventional 
therapy [152]. Reduced expression of anti-fibrotic miR29, for example, is associated with 
increased atrial fibrosis and vulnerability to AF in a canine ventricular tachypacing-induced 
HF model [153]. Similarly, miR29 expression was reduced in patients with cAF and plasma 
levels of miR29b could be used to predict the outcome in pAF-patients [154]. 
Taken together, substratification of AF phenotypes may allow the combination of different 
mechanism-specific drugs (direct anti-arrhythmic atrial-selective channel-modifying drugs as 
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well as modifiers of remodeling processes, inflammation etc.) and interventional therapies 
guided by the disease subtypes [128]. 
Application of human induced pluripotent stem cell-derived cardiomyocytes in experimental 
and clinical electrophysiology 
Application of hIPSC-CM may theoretically provide the unique opportunity to investigate 
cardiac electrophysiology of any individual in a non-invasive way and is expected to help 
closing the gap between experimental and clinical electrophysiology. Ideally, hIPSC-CM 
could predict arrhythmogenic risk and efficacy of drugs, contributing to personalized 
medicine. From a broader perspective, studies on cellular electrophysiology would no longer 
be restricted to tissue harvested during open-heart surgery, allowing intense work on 
undiseased ventricular tissue. hIPSC-CM should enable repeated investigations, making 
long and complex functional studies even at different laboratories possible. Classic 
transgene approaches applied in hIPSC-CM could be used to study heart electrophysiology 
on a human background. Since hIPSC-CM can be kept in culture over weeks or even 
months; they could be used to study effects of “long-term” exposure to drugs or increased 
mechanical load. From this perspective, one could assume that hIPSC-CM could dominate 
cellular cardiac electrophysiology in the near future; however, there are several critical issue 
to be addressed. 
A central question is how closely hIPSC-CM resemble native human cardiomyocytes, in 
particular: (1) What type of cardiomyocytes do hIPSC-CM present? Ventricular, atrial, nodal 
or just a mixture of them [155]? (2) What is the repolarization reserve of hIPSC-CM 
compared to classic approaches based on animal and undiseased human ventricular tissue 
[156]? (3) Is the relatively depolarized RMP an intrinsic peculiarity of hIPSC-CM? (4) Are 
there other reasons for automaticity in hIPSC-CM than low RMP [157]? (5) How to normalize 
APD when measured at different spontaneous beating rates? Can hIPSC-CM be used as 
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biological pacemakers [158]? (6) Do hIPSC-CM recapitulate basic findings on cAMP/PKA-
mediated contribution to heart pathophysiology? (7) Can hIPSC-CM be used as a model to 
study human atrial electrophysiology [159]? 
To answer these questions, a wide range of cellular electrophysiological techniques is 
needed. Since it is likely that many of these questions relate to differences in the 
differentiation and culture of hIPSC-CM, close collaboration between cellular cardiac 
electrophysiologists and experts in stem cell biology will be mandatory. 
Gene- and cell-based therapy 
Gene therapy offers greater selectivity than small molecule-based or interventional 
treatment. The gene of interest is packaged into viral or non-viral carriers and delivered to 
the target area via direct injection or using catheter-based techniques, providing the 
advantage of site-restricted action in contrast to systemic application of drugs. Gene therapy 
for heart rhythm disorders is currently being evaluated in preclinical stages. To date, no 
antiarrhythmic gene therapy drug is commercially available or has been investigated in 
clinical trials. Antiarrhythmic effects against AF and ventricular tachycardia, and restoration or 
suppression of pacemaker activity were successfully achieved in promising pre-clinical gene 
therapeutic approaches [160]. Cell-based approaches for the treatment of heart rhythm 
disorders have almost exclusively focused on the generation of biological pacemaker activity 
[161]. However, in terms of clinical translation most gene and cell therapy strategies are still 
in early stages of a complex developmental process that involves extensive research and 
caution prior to widespread human application. 
Limitations of the translation of current approaches 
One major challenge of efficient translation is the presence of multiple pathophysiological 
mechanisms in a single disease entity or even an individual patient. Computational 
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cardiology technologies, comprehensive genetics, or the use of biomarkers may help to 
overcome this challenge. In addition, the effect of underlying mechanisms on clinical 
arrhythmia manifestations may vary with time, reducing the potential for the establishment of 
more generalized treatment recommendations in some cases. Furthermore, experiments 
using cells derived from animal models and hIPSC-CM do not fully reconstitute phenotypes 
observed in arrhythmia patients, highlighting the increased need for research employing 
human cells. In terms of personnel, it is important to recognize that clinical heart rhythm 
specialists and translational scientists are rarely located in the same unit. In fact, in most 
cases they do not share the same academic institution or hospital, preventing 
multidisciplinary exchange, interaction, and collaboration. Other organizational factors pose 
limitations to translation as well. In clinical electrophysiology departments, the combined 
workload produced by clinical and scientific work, in addition to administrative duties, writing 
of grant applications and academic obligations, create an unfavorable environment for 
focused application of basic findings into optimized patient care. Finally, limited options to 
obtain substantial funding, particularly for translational electrophysiologists in training, require 
optimization to promote this emerging field in the long term. 
Future perspectives 
The ability of an antiarrhythmic intervention to prevent cardiac arrhythmia depends on its 
capacity to suppress the underlying disease mechanisms. Despite great advances in the 
mechanistic understanding of inherited channelopathies, translation of mechanism-based 
novel therapies into clinical use remains challenging due to problems in designing and 
funding clinical studies with sufficient power in these rare diseases, particularly for "second 
use" applications of already approved drugs. Additional electrophysiological targets currently 
in the pipeline include previously unrecognized ion channels, regulatory signaling pathways, 
structural alterations such as fibrosis that may be targeted by “upstream therapy”, and 
epigenetic modulation of cardiac electrophysiology. The impact of different comorbidities on 
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proarrhythmic mechanisms is increasingly recognized as well. Identification of remodeling 
associated with specific concomitant diseases is expected to enable personalized 
approaches, for example in patients with AF. It would thus be of great importance to improve 
funding for translational studies implementing basic science into clinical approaches. 
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A call to establish and support cellular electrophysiology programs in clinical 
electrophysiology 
Multiple efforts are underway to standardize training and education of heart rhythm 
specialists in Germany and Europe. At the National level in Germany, a curriculum required 
to achieve heart rhythm specialist qualification (“Zusatzqualifikation Spezielle Rhythmologie”) 
conveys detailed clinical content on heart rhythm disorders [162]. By contrast, cellular and, 
particularly, translational electrophysiology is not addressed in detail. Similarly, within the 
European Core Curriculum for the Heart Rhythm Specialist proposed by the European Heart 
Rhythm Association [163], training focusses virtually entirely on clinical knowledge and 
practical skills, and basic science knowledge on arrhythmias is included only to a small 
extent. However, basic science plays a crucial role in clinical medicine and the health care 
system by producing novel technologies, drugs, biomarkers, and mechanistic knowledge as 
basis for patient-oriented therapy that may ultimately serve to save health care budgets by 
delivering the right therapy to a specific patient. In accordance, the Diploma of Advanced 
Studies in Cardiac Arrhythmia Management (DAS-CAM), organized by the European Society 
of Cardiology and European Heart Academy in collaboration with Maastricht University, 
explicitly includes sessions on arrhythmia mechanisms and translational electrophysiology. 
Despite the recognition and appreciation of translational electrophysiology by European and 
United States societies for heart rhythm disorders [164,165], a relevant gap is evident 
between current patient therapy on one side and the implementation of basic research 
knowledge into clinical decision making on the other. The German Cardiac Society Working 
Group on Cellular Electrophysiology assumes the responsibility for the promotion of 
translational electrophysiology within the field of heart rhythm disorders. Therefore, this 
group of authors proposes the establishment of cellular electrophysiology programs in 
institutions providing medical care to arrhythmia patients, to optimize patient care through 
multi-disciplinary diagnostic and therapeutic approaches. In addition, the Working Group 
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intends to provide a platform for the coordination of nationwide research efforts in the field of 
translational electrophysiology. This platform is designed to optimize collaborative scientific 
projects and third-party funded research programs. Furthermore, a “Pathophysiology and 
Translational Electrophysiology Curriculum” is called for to provide a platform for 
standardized education of heart rhythm specialists in this hitherto underrepresented field. 
Ultimately, this educational curriculum may be advanced into a formal “Sachkundekurs: 
Cellular and Translational Electrophysiology” as part of the “Zusatzqualifikation Spezielle 
Rhythmologie”. Finally, improved funding for research and education in the field of 
translational electrophysiology, especially within dedicated translational units, is required to 
successfully achieve the proposed goals. Anticipated advantages and added value of such 
infrastructure and programs are summarized in Table 2. A coordinated effort of researchers, 
translational scientists and clinicians is required to achieve “true” translation and to obtain 
maximum benefit for optimized therapy of patients affected by heart rhythm disorders.  
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Tables 
Table 1. VT in ischemic cardiomyopathy: a systematic analysis of significant  mRNA level 
alterations (transcriptomics) of the infarction border zone may provide novel antiarrhythmic 
drug targets. For further information see text (Modified after [96]) 
Process Gene Averaged transcript level fold change (BZ-D vs. BZ) 
Death of Cardiomyocytes PSRC1 6.06 
NDFIP1 6.05 
LAMP2 3.10 
Acute Inflammation CXCL6 9.23 
IL6 8.18 
IL23R 8.08 
HCK 7.54 
CXCL9 5.27 
Regression of 
Inflammatory Signaling 
THBS1 3.64 
TNFAIP6 3.39 
Stimulation of 
Extracellular Matrix by 
Cardiac Fibroblasts 
ITGA8 5.04 
SMURF1 2.84 
TIMP1 2.14 
THBS2 2.09 
Formation of Mature Scar COL8A1 5.1 
FN1 4.46 
TNN 3.93 
TNC 7.77 
STAT3 3.64 
GPNMB 3.49 
LMNA 3.48 
POSTN 3.38 
ACAN 2.85 
COL1A2 2.43 
VCAN 2.41 
CTGF 2.32 
COMP 2.30 
  
 57 
 
Table 2. Benefits of dedicated cellular electrophysiology programs associated with clinical 
electrophysiology departments 
Patient care and 
translation 
Ready translation of basic scientific findings into clinical 
application and improved patient diagnosis and treatment. 
Basic science and 
“reverse” translation 
Clinical findings and challenges trigger and guide scientific 
hypotheses and approaches. 
Education Training of “translational electrophysiologist” physician scientists 
[165,166] who display both basic science expertise and 
specialized clinical knowledge in heart rhythm disorders. 
Infrastructure Creation of an environment that allows for a combined scientific 
and clinical approach to specific challenges in the understanding 
and management of arrhythmias. 
Network Implementation of a “German Cardiac Society Working Group on 
Cardiac Cellular Electrophysiology Network for Translational 
Research” provides a platform for nationwide interdisciplinary 
research and application. 
Funding Generation of optimized prerequisites for successful acquisition of 
funding for research efforts. 
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Figures 
Figure 1: Cellular mechanisms underlying ectopic activity. A, Abnormal automaticity is 
caused by spontaneous diastolic depolarization to a threshold value for activation. B, C 
Abnormal membrane depolarizations preceding full repolarization (B, early 
afterdepolarizations [EADs]) or after completion of the action potential (C, delayed 
afterdepolarizations [DADs]) or repolarization (early afterdepolarizations [EADs]) may also 
cause spontaneous activity. (Replotted with kind permission from [167]) 
 
Figure 2: Current concepts of functional reentry. A, The leading circle concepts is based 
on a reentering excitation travelling around a functional refractory and therefore unexcitable 
core. The circuit size is determined by the wavelength i.e. the distance travelled by the 
cardiac impulse in one effective refractory period (ERP), given by the product of conduction 
velocity (CV) and ERP. B, In the spiral wave concept reentry occurs around an excitable but 
continuously unexcited corecore and maintenance depends on balance of current-
source/tissue-excitability (favoring propagation) and current-sink (impairing propagation). 
(Adapted with kind permission from [9]) 
 
